v3.26.3
Equity (Tables)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Schedule of Warrants Activity
    Six months ended June 30,  
    2026     2025  
   

Number of
warrants

   

Weighted

average

exercise price

   

Number of
warrants

   

Weighted average

exercise price

 
Outstanding at beginning of period     504,487     $ 23.09       509,674     $ 30.15  
Issued     -     $ -       -     $ -  
Exercised     -     $ -       -     $ -  
Forfeited and expired     (11,972 )   $ 375.00       (1,517 )   $ 150.00  
Outstanding and exercisable at end of period     492,515     $ 14.53       508,157     $ 29.74  
Schedule of Warrants Outstanding

Set forth below is data regarding the range of exercise prices and expiration dates for warrants outstanding at June 30, 2026:

 

Number of Warrants     Exercise Price Per Share     Issuance date   Expiration date
  238,096     $ 21.00     May 29, 2024   November 29, 2029 (i)
  8,335     $ 26.25     May 29, 2024   May 27, 2029 (ii)
  1,667     $ 48.75     November 26, 2024   February 2, 2027
  1,667     $ 63.75     November 26, 2024   February 2, 2027
  116,667     $ 15.00     November 24, 2025   November 30, 2030
  79,708     $ 0.015     November 24, 2025   None
  46,375     $ 0.015     November 24, 2025   None
  492,515                  

 

(i) The earlier of (a) November 29, 2029 and (b) the 60th day following the Company’s public announcement of its filing with the U.S. Food and Drug Administration for approval for AllocetraTM’s osteoarthritis related indication (the “Series B Milestone Event”).

 

(ii) The earlier of (a) May 27, 2029 and (b) 60 days following the Series B Milestone Event.